PRO DEX Business Summary

Pro-Dex Inc. (PDEX) operates as a specialized medical device manufacturer primarily utilizing an Original Equipment Manufacturer (OEM) contract model to design, develop, and produce high-precision powered surgical instruments. The company generates revenue through three primary streams: the sale of proprietary and customer-funded surgical drivers and shavers, high-margin repair services for legacy handpieces, and specialized engineering consulting. Its business is organized into three core clinical segments—Orthopedic, Thoracic, and Cranio-Maxillofacial (CMF)—with a strategic focus on autoclavable, battery-powered, and electric multi-function tools. While Pro-Dex maintains a dominant niche position in the CMF market and has recently expanded its thoracic portfolio, it faces significant customer concentration risk, with its largest partner accounting for approximately 75-85% of total revenue. In the broader medical equipment landscape, Pro-Dex competes with firms such as OrthoPediatrics (KIDS), ClearPoint Neuro (CLPT), and Brainsway (BWAY), positioning itself as a high-efficiency, small-cap alternative to larger diversified manufacturers by offering faster development cycles and specialized intellectual property in torque-limiting software. Founded in 1978, the company is currently led by President and CEO Richard L. ("Rick") Van Kirk, who joined in 2006 and has over 40 years of manufacturing experience, including previous leadership roles at Comarco Wireless Technologies and Dynacast. He is supported by CFO Alisha Charlton, a former KPMG auditor and Chief Accounting Officer at Comarco, who has overseen the company’s financial strategy since 2015. The leadership team also includes Angelita Domingo, Director of Quality Systems and Regulatory Affairs, and Jorge Cuervo, who joined in late 2023 as Director of the Project Management Office following a 25-year career in global operations at Bio-Techne. The Board of Directors is chaired by Nicholas Swenson, the CEO of Air T, Inc., and includes notable institutional representation from Raymond Cabillot, CEO of Farnam Street Capital. This seasoned leadership group has focused recent efforts on transitioning to next-generation product shipments and utilizing capital gains from strategic investments, such as their successful exit from Monogram Technologies, to fund capacity expansion and internal R&D.